Onercept
Alternative Names: r-hTBP; r-hTBP-1; r-TBP-1; TBP; TBP 1; TBP I; TNF-BP1; Tumour necrosis factor antagonist; Tumour necrosis factor binding protein 1Latest Information Update: 24 Oct 2021
Price :
$50 *
At a glance
- Originator Weizmann Institute of Science
- Developer Yeda
- Class Anti-inflammatories; Antirheumatics; Polyethylene glycols; Recombinant proteins
- Mechanism of Action Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Crohn's disease; Endometriosis; Psoriasis; Psoriatic arthritis; Reperfusion injury; Rheumatoid arthritis; Septic shock
Most Recent Events
- 05 Jan 2007 Serono has been acquired by Merck KGaA
- 06 Sep 2005 Discontinued - Phase-II for Crohn's disease in Canada (Parenteral)
- 06 Sep 2005 Discontinued - Phase-II for Crohn's disease in Italy (Parenteral)